Introduction
Intercellular adhesion molecules play important roles in lymphocyte-mediated immune responses (reviewed in (1, 2) ). In order to mediate their immune functions, CTL and NK cells require engagement of intercellular adhesion molecules on these effector cells to their respective ligands expressed on target cells.
We previously reported an adhesion molecule DNAM-1 (CD226) that is a member of immunoglobulin superfamily containing two Ig-like domains of the V-set and is encoded by a gene on human chromosome 18q22.3 (3, 4) . CD226 is a ~65 kDa glycoprotein expressed on the majority of NK cells, T cells, monocytes and platetelets and a subset of B lymphocytes. We observed that anti-CD226 monoclonal antibody (mAb) blocked CTL and NK cell-mediated cytolysis of some, but not all, tumor targets, suggesting that certain tumor cells may express cell surface ligands for CD226 (3) .
CD226 is co-immunoprecipitated with LFA-1 from NK cells and anti-CD3-stimulated T cells (5) . Cross-linking LFA-1, but not CD226, on CD3-stimulated T cells resulted in tyrosine phosphorylation of CD226, which is mediated by the Src-family tyrosine kinase Fyn. Recently, we have reported that CD226 is involved in LFA-1-mediated Tahara-Hanaoka, et al 4 costimulatory signals for triggering naive T cell differentiation and proliferation (6) .
However, it has been uncertain how adhesion and intracellular signaling are mediated by the complex of LFA-1 and CD226. To address this issue, it is necessary to identify the CD226 ligand and determine the structural requirements involved in CD226 binding.
In the present study, we describe the structural characteristics of CD226 interaction with its ligands and the functional relationship of CD226 with LFA-1.
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Materials and Methods

Antibodies, cells and cDNA
The anti-CD155 mAb TX-24 and the anti-CD112 mAb TX-31 were generated by standard methods. Anti-CD155 (P286) and anti-CD226 (DX11) were generously provided by Dr. Akio Nomoto (University of Tokyo) and by Dr. Joe Phillips (DNAX, Palo Alto, CA), respectively. Anti-CD111 (R1.302.12) and anti-CD112 (R2.477.1)
were purchased from Coulter/Immunotech (Marseille). Anti-CD18 (TS1/18) and anti-mouse ICAM-2 (3C4) were obtained from ATCC and BD Pharmingen, respectively. Human CD3+ T cells and CD3-CD56+ NK cells were purified from peripheral blood by using a MACS Magnetic cell sorting system (Miltenyi Biotec) or by sorting using flow cytometry and were cultured in the presence of IL-2 (100 U/ml). CD155α and CD155δ cDNAs and CD111 cDNA were kindly provided by Dr. Akio Nomoto and Dr.
Yoshimi Takai (Osaka University, Osaka), respectively.
Expression of the Fc Fusion Proteins
CD226-Fc fusion protein was described previously (7) . CD155-Fc and CD112-Fc Tahara-Hanaoka, et al 6 fusion proteins were also generated with chimeric cDNAs of the entire extracellular domain of CD155 or CD112 with the human IgG 1 Fc, as described (7) . The ICAM-1-Fc was purchased from R & D Systems (Minneapolis).
Surface Plasmon Resonance Experiments
Binding experiments were carried out using surface plasmon resonance as implemented in the BIAcore 3000 (BIAcore AB, St. Albans, UK). For experiments to determine the binding affinity of CD226 for its ligands, CD226-Fc (20 μg/ml in 10 mM sodium acetate, pH 4.5) was directly immobilized to the CM5 sensor chip surface by ammine coupling using the manufacture's kit (BIAcore AB) and an activation time of 5 min, resulting in 3261-3640 resonance units (RU) of immobilized ligand. Equilibrium binding analysis was performed as described (8) . The following equation was used for calculation of dissociation constants based on equilibrium binding analysis. Interferon-γ concentrations in culture supernatants were determined using an ELISA kit (Biosource International, Camarillo, CA).
Results
Cloning of CD226 ligands
To characterize the CD226 ligand, we examined the expression of CD226
ligand on several tumor cell lines by staining with the CD226-Fc. As shown in Fig 1A, CD226-Fc bound to non-hematopoietic tumor cell lines, including the osteosarcoma cell HOS, the microglioma cell U87-MG and the rhabdomyosarcoma cell RD, but not to the EBV-transformed B lymphoblastoid cells, T cell leukemia H9 and monocytic leukemia U937.
To identify a cDNA encoding the CD226 ligand, we screened Ba/F3 cells infected with a retroviral cDNA library prepared from the HOS cells, using CD226-Fc as a probe. We isolated a cDNA that encodes the human poliovirus receptor (PVR) α (CD155). CD226-Fc stained Ba/F3 cells transfected with the isolated PVRαcDNA, indicating that PVRα is capable of binding with CD226 ( Fig 1B) . We also found that CD226-Fc stained the transfectant expressing PVRδ (Fig 1B) , an isoform of CD155
with the same ectodomain sequence as PVRα (9, 10) . CD155 is a member of the However, EBV-B cells that did not bind CD226-Fc also did not express CD155 or CD112 (Fig 1C) .
Affinity of CD226 for its ligands
To confirm the specific interaction of CD226 with CD155 and CD112, we generated human CD155-Fc and CD112-Fc proteins. These soluble fusion proteins bound to the BW5147 transfectant expressing human CD226, as determined by flow Tahara-Hanaoka, et al 10 cytometry (Fig 2A) . However, we observed that the mean fluorescence intensity of the CD155-Fc-binding transfectant was significantly higher than the CD112-Fc-binding transfectant, although the same amounts of the fusion proteins were used for staining (Fig 2A) . Conversely, the mean fluorescence intensity of the CD226-Fc-binding transfectant expressing CD155 was higher than that of the transfectant expressing CD112 (Fig 2A) , in spite of the similar amount of expression of CD155 and CD112 on each transfectant (data not shown). These results suggest that the affinity of CD155 to CD226 may be higher than that of CD112 to CD226.
We therefore analyzed CD226-Fc: ligands (i.e., CD155-Fc and CD112-Fc)
interactions by using surface plasmon resonance. transfectants expressing CD155 or CD112. It is of note that CD112-Fc also bound to the transfectant expressing CD112 itself (Fig 1A) , consistent with the previous report that CD112 can also mediate homophilic binding (12, 13) . In fact, we observed homotypic cell aggregation of the BW5147 transfectant expressing CD112, but not of the BW5147 transfectants expressing CD155 or CD226 (data not shown). To examine whether the homophilic interaction of CD112 adversely affects CD226-Fc binding to the BW5147 transfectant expressing CD112, the transfectants was pretreated with the anti-CD112 mAb (R2.477.1), which recognizes an epitope at one of the C-set Ig-like domains of CD112 (14) and blocks homophilic binding of CD112 (13), and then stained with CD226-Fc. As shown in Fig. 2C , CD226-Fc binding to the CD112 transfectant was augmented substantially after pretreatment with the R2.477.1mAb, while TX-31
anti-CD112 mAb partially inhibited CD226-Fc binding to the CD112 transfectant.
These results suggest that CD226 binding to CD112 on cell surface may be impaired by homophilic interaction of CD112.
Interactions of CD226 and its ligands induce NK and T-cell-mediated cytotoxicity
To determine whether expression of CD226 ligands renders cells more susceptible to cytolysis, we performed cytotoxicity assays using IL-2-activated T cells anti-CD112 (TX-31) mAbs partially, rather than completely, inhibited the cytotoxicity (Fig 3A) , probably because these mAbs incompletely blocked interaction of CD226
with the ligands (Fig 2C and data not shown) . In contrast to TX-31 anti-CD112 mAb, R2.477.1 anti-CD112 mAb augmented the CD226-Fc binding to CD112-expressing transfectant by abrogating CD112 homophilic interaction (Fig 2C) , raising a question whether R2.477.1 anti-CD112 mAb increases cytotoxicity of T cells or NK cells against anti-CD112 mAb (Fig 3B) , in spite of increase of CD226-Fc binding to CD112-expressing transfectant (Fig 2C) . The molecular mechanism of this observation is unclear at present. Nonetheless, these results indicate that CD112 as well as CD155 is a functional ligand for CD226.
CD226 and LFA-1 cooperate in cytotoxicity and cytokine secretion mediated by T cells and NK cells
BW5147 cells express murine ICAM-2 (data not shown) that interacts with
LFA-1 (CD11a/CD18) on human T and NK cells (15). As described above, acquisition of CD226 ligand expression rendered BW5147 cells more susceptible to IL-2-activated T cell and NK cell-mediated cytotoxicity (Fig 3 and Fig 4A) . Interestingly, addition of anti-LFA-1 or anti-murine ICAM-2 mAbs that prevent interaction between human LFA-1 and mouse ICAM-2 inhibited the IL-2-activated T cell-mediated cytotoxicity against the BW5147 transfectants expressing CD155, CD112 or both (Fig 4A) . These To examine whether CD226-mediated cytotoxicity requires LFA-1 ligation, we established LFA-1-deficient NK clones derived from a patient with leukocyte adhesion deficiency (LAD) (Fig 4C) . While cross-linking CD226 with anti-CD226 mAb induces re-directed cytotoxicity against Fc-receptor-bearing P815 by normal NK cells expressing LFA-1 (3,5), anti-CD226 mAb did not induce the re-directed cytotoxicity by the LAD NK clones (Fig 4D) , consistent with our previous report (5) 
Discussion
By expression cloning using CD226-Fc as a probe, we have identified the PRR family members CD155 (PVR) and CD112 (nectin-2/PRR-2) as ligands for CD226 (Fig 1, 2) . We have shown that acquisition of human CD155 and/or CD112 rendered mouse BW5147 cells more susceptible to IL-2-activated T cell and NK cell-mediated cytotoxicity, and killing was specifically inhibited by anti-CD226 mAb (Fig 3A) , demonstrating functional interactions between CD226 and its ligands CD155 and CD112. Very recently, Moretta and colleagues have also independently identified CD155 and CD112 as functional CD226 ligands by a different strategy (i.e. generating monoclonal antibodies that block NK cell-mediated cytotoxicity against certain tumors) (16). In this paper, we have explored further the structural and functional characteristics of CD226 interactions with its ligands. We have demonstrated that CD155 and CD112 are often simultaneously expressed on cells (Fig 1C) , raising a question how CD226 interaction with each ligand is regulated. Although the binding affinities of CD226-Fc to CD155-Fc and to CD112-Fc were comparable (Fig 2B) , homophilic interaction of cell surface CD112 may adversely affect CD226-Fc binding Tahara-Hanaoka, et al 17 to CD112 (Fig 2A, C) , suggesting that CD226 may prefer CD155 to CD112 as a physiological ligand. However, abrogation of CD112 homophilic interaction by R2.477.1 anti-CD112 mAb inhibited, rather than augmented, CD226-mediated cytotoxicity, in spite of increase of CD226 binding (Fig 3B) . These results suggest that, although homophilic interaction of CD112 may decrease affinity of CD226 binding to CD112, it may accumulate CD226 at immunological synapse, resulting in increase of its avidity that is capable of mediating activation signal for cytotoxicity in T cells and NK cells. Further studies are required to explore the molecular and functional relationship between CD226 and CD112.
In this paper, we have formally demonstrated that LFA-1 and CD226
cooperate in triggering T cell and NK cell-mediated cytotoxicity and cytokine secretion, using the transfectants expressing CD226 ligands (CD155 and/or CD112 or the soluble CD155) and LFA-1 ligand (ICAM-1 proteins) (Fig 4A, B) . These results were consistent with our observation that cross-linking CD226 with anti-CD226 mAb did not induce re-directed cytotoxicity against P815 by LFA-1-deficient LAD NK clones ( Fig   4D) , suggesting a requirement of LFA-1 for CD226-mediated cytotoxicity. However, Tahara-Hanaoka, et al 18 LAD NK clones acquired ability to mediate anti-CD226-dependent re-directed cytotoxicity after stimulation with PMA (Fig 4D) . Furthermore, IL-2-activated polyclonal LAD T cells and NK cells exhibited CD226-mediated cytotoxicity (Fig 4E) .
These results suggest that whether or not CD226-mediated cytotoxicity essentially 
